GB Patent

GB2531283A — Use of cannabidiols in the treatment of degenerative skeletal muscle diseases

Assigned to GW Pharma Ltd · Expires 2016-04-20 · 10y expired

What this patent protects

One or a combination of the phytocannabinoids cannabidiol (CBD); cannabidivarin (CBDV); and tetrahydrocannabivarin (THCV), for use in the treatment of degenerative skeletal muscle disease, is provided. Preferably the degenerative skeletal muscle disease is Duchenne muscular dystr…

USPTO Abstract

One or a combination of the phytocannabinoids cannabidiol (CBD); cannabidivarin (CBDV); and tetrahydrocannabivarin (THCV), for use in the treatment of degenerative skeletal muscle disease, is provided. Preferably the degenerative skeletal muscle disease is Duchenne muscular dystrophy (DMD). Preferably the dose of the cannabinoids is between 1 and 1000mg/kg/day.

Drugs covered by this patent

Patent Metadata

Patent number
GB2531283A
Jurisdiction
GB
Classification
—
Expires
2016-04-20
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.